Summary Angiogenesis is the formation of new blood vessels from the existing vasculature. Vascular endothelial growth factor (VEGF) is an endothelium-specific angiogenic factor strongly implicated in pathological angiogenesis. In this study, the mRNA and protein expression of the four alternatively spliced VEGF isoforms (121, 165, 189 and 206 amino acids) were examined in normal and malignant breast tissues. Three VEGF transcripts were detected in both (121>165>189), whereas only VEGF165 protein was detected. The tumours expressed more VEGF mRNA (P = 0.02) and protein (P < 0.0001), with eight-fold more VEGF protein generated per mRNA unit (P = 0.009). To examine this further, the expression of elF-4E, a translation initiation factor, was examined. Increased elF-4E mRNA levels were detected in the tumours (P < 0.0001) that correlated with VEGF mRNA (P = 0.0002), implying co-regulation of these genes. VEGF mRNA expression was elevated in tumours expressing the epidermal growth factor receptor (P < 0.01), but there was no difference according to oestrogen receptor status (P = 0.9), node status (P = 0.09) or between differing histologies (P = 0.4). These data suggest that elevated VEGF protein expression, by both enhanced transcription and translation, is a potential means by which tumour angiogenesis is induced in breast carcinomas. VEGF expression is also significantly associated with factors correlating with a poor outcome, implying a role in progression of this disease.
Correspondence to: AL Harris as urokinase plasminogen activator and collagenase (Pepper et al, 1992; Unemori et al, 1992) .
VEGF expression has been identified at the mRNA or protein level in a range of malignancies, including gastrointestinal (Brown et al, 1993a; Hsu et al, 1995; Shiraishi et al, 1995; Takahaski et al, 1995; Warren et al, 1995; Maeda et al, 1996) , renal (Brown et al, 1993b; Sato et al, 1994; Takahaski et al, 1994) , bladder (Brown et al, 1993b) , lung (Mattern et al, 1995) , ovarian (Boocock et al, 1995; Olson et al, 1995) , endometrial (Harrison-Woolrych et al, 1995) , cervical and hepatocellular carcinomas (Mise et al, 1996) In human breast carcinoma, VEGF mRNA expression has been reported to be higher in tumour cells compared with normal ductal cells using in situ hybridization . The levels of VEGF protein have been quantitated in this malignancy and found to correlate with increased microvessel density (Toi et al, 1994; and early relapse in primary breast carcinoma (Toi et al, 1994) . A recent study has demonstrated that VEGF protein levels in tumour samples are significantly higher in tumours compared with matched normal samples (Yoshiji et al, 1996) .
To date, all studies of VEGF in breast carcinoma and normal tissues have examined total mRNA and protein. There are, however, four isoforms with significantly different biochemical and biological effects that are generated by alternative splicing (Houck et al, 1991; Tischer et al, 1991) . The smallest isoform, VEGF121, is freely soluble and does not bind heparin. The inclusion of more cationic exons in the next two isoforms, VEGF165 and VEGF189, confers heparin-binding properties (Tischer et al, 1991; Ferrara et al, 1992) resulting in binding to the extracellular matrix after secretion Park et al, 1993) . This heparin-binding fragment has been shown recently to confer an increased mitogenic potency on the VEGF165 compared with the VEGF 121 isoform (Keyt et al, 1996) , although there are no reports on the relative potency of the VEGF189 isoform. The largest isoform, VEGF206, has only been identified in a fetal liver library and has similar properties to VEGF189 (Houck et al, 1991) , but little is known about its biological relevance.
VEGF expression is regulated by a number of factors including hypoxia and hypoglycaemia in glioblastoma spheroids (Shweiki et al, 1995) , and hormones in tissues from the female reproductive tract (Cullinanbove and Koos, 1993) . Hypoxia, a feature of all solid tumours, is the most potent stimulus, and its induction results from a combination of increased transcription and mRNA stability. Recently, however, a post-transcriptional mechanism for VEGF regulation has been identified, acting through the enhancement of recruitment and binding of the mRNA to the ribosome. The mRNA of growth factors such as VEGF characteristically have long 5' untranslated regions (UTRs) with complex secondary structures that render them inefficiently translated (Kevil et al, 1996) . eIF-4E is a polypeptide that binds the 7-methylguanosine-containing cap of mRNA, unwinds the 5' UTR of the target mRNA facilitating the identification of the translation start site by the ribosome. Elevated eIF-4E levels have been associated with increased growth rates and transformation of cell lines (De Benedetti and Rhoads, 1990) , and increased levels of VEGF protein (Kevil et al, 1996) . Increased expression of eIF-4E has been found in both breast carcinoma tissues compared with fibroadenomas (Kerekatte et al, 1995) and breast carcinoma cell lines compared with normal breast cell lines (Anthony et al, 1996) and may represent a means of regulating expression of genes including angiogenic factors and subsequent tumour growth (Kevil et al, 1996) .
The aims of this study were to quantify and locate the expression of the VEGF isoforms at the mRNA and protein levels in both normal and breast carcinoma tissues. I'he relationship between mRNA and protein expression was studied in tumours vs normal tissues as well as the potential role of eIF-4E in breast carcinoma in regulating that expression. The levels of VEGF mRNA, protein and eIF-4E were also compared with factors known to affect prognosis such as oestrogen receptor (ER), epidermal growth factor receptor (EGFR), node status and histology of the tumours.
MATERIALS AND METHODS
Isolation of RNA from cells and tissues and ribonuclease protection assay (RPA) Total RNA was prepared by acid guanidinium thiocyanatephenol-chloroform extraction (Chomczynski and Sacchi, 1987) . For the ribonuclease protection assays, radiolabelled riboprobes were synthesized with [Qc-32P]CTP (Amersham, UK) from linearized plasmid DNA using the in vitro transcription method (Ausubel et al 1987) .
Two VEGF riboprobes were used: the first was designed to protect the full length of the smallest isoform (VEGF1 21 yielding a 471-base band, with a lower band of 427 representing the remaining isoforms). This 520-base probe was generated by linearizing the full-length cDNA for VEGF121 (including 26 bp of 3' untranslated sequence) cloned into pBluescript SK with EcoRV and transcribing with T7 RNA polymerase. To determine the isoforms contributing to this second smaller band, a new construct was designed to protect its largest fragment, VEGF,89, with the remaining isoforms forming two bands lower on the gel. The cDNA coding for the mature VEGF1 89 protein was cloned into BS KS + in the XbaI and EcoRI sites and the probe generated using NotI and T3 polymerase. The largest protected fragment was 567 bases, with a 345-bp fragment formed from both the VEGF121 and the VEGF165 isoforms, and a third band of 150 bases representing VEGF165 alone. The generation of the eIF-4E riboprobe has been described elsewhere (De Benedetti et al, 1991) .
RPAs were performed essentially as described (Ausubel et al, 1987 ) with a minimum of 10-c.p.m. of each antisense riboprobe hybridized overnight at 55°C to each sample with 10 ltg of transfer RNA as a negative control. The RNAase digestion of the unhybridized RNA fragments was performed the next day by adding 350,l of RNAase digestion buffer with 40,g ml' RNAase A and 1000 units ml' RNAase T1 to each sample and incubating for 30 min at room temperature. The RNAases were inactivated by adding 12.5 gl of a mixture containing 16% sodium dodecylsulphate (SDS) solution with 4 tg gl-' proteinase K and incubating at 37°C for 15 min. After phenol extraction and precipitation in 2 volumes of ethanol, the samples were resuspended and loaded onto a 6% polyacrylamide/urea sequencing gel followed by autoradiography.
The resulting bands were quantitated densitometrically (Bioimage densitometer, Millipore) and signals normalized to the external control. This control was formed from the hybridization of a sense and antisense riboprobe to glyceraldehyde-3-phosphate (GAPDH), with the sense riboprobe generated by linearizing the construct 30 bases beyond the end of the GAPDH sequence. This gives two protected fragments: the endogenous gene (120 bp) and the external control fragment (150 bp). Before aliquotting, each sample was run on a 1 % agarose gel under RNAase-free conditions, and the RNA concentration measured spectrophotometrically, as described in Scott et al (1997) .
In situ hybridization
In situ hybridizations were performed using single-stranded RNA 35S-labelled riboprobes hybridized with 4-jtm sections of formalinfixed, paraffin-embedded tissue prepared earlier by dewaxing in xylene/0.1% DEPC then rehydrating in serial washes of 100%, 80%, 60% and 30% ethanol. The sections were then permeabilized with proteinase K (20 gg ml') for 10 min, washed thoroughly in phosphate buffered saline (PBS) and the tissues acetylated with 0.1 M triethanolamine and acetic anhydride (1.25 ml in 500 ml) before dehydration in ethanol in the reverse order mentioned above, ready for hybridization. The sections were then incubated with 106 c.p.m. of riboprobe in hybridization buffer (Senior et al, 1987 ) that had been heated to 80°C, and incubated overnight at 55°C. After washing extensively in 50% formamide at 50°C, the sections were incubated with 100 tg ml' RNAase A for 1 h to remove the unhybridized riboprobe. The slides were then washed, fixed in 30% ethanol/0.3 M ammonium acetate, air dried and placed in emulsion (Senior et al, 1987) . After 7 days, the slides were developed, washed and the signal visualized, and compared with Giemsacounterstained light-field sections. A f-actin hybridization was used as a positive control.
Extraction and analysis of tumour membranes and cytosols
Tumour membranes, cytosols and nuclei were prepared as described previously (Sacks et al, 1993) . Briefly, the tumours were frozen in liquid nitrogen, ground up in a similar way as for RNA extraction before addition of an ice-cold Hepes/EDTA buffer containing proteinase inhibitors, then homogenized using a Dounce homogenizer. The homogenate was centrifuged in a bench-top centrifuge at 4°C, yielding the first fraction containing mostly DNA and other nuclear debris, and was retained as the 'nuclei' fraction. The supernatant was removed carefully and centrifuged at 100 000 g to bring down any membrane fractions (the 'membrane' fraction while the supernatant forms the 'cytosol' fraction).
ELISA analysis of tissues
The VEGF protein levels were measured using ELISA (R&D Systems, Abingdon, UK). As this ELISA had not been used previously for assaying such samples, the accuracy was validated by comparing the VEGF protein standards diluted 50:50 with the sample buffer (Tris-buffered saline pH 7.5) with that provided by the manufacturer, as well as the effects of adding a constant amount of sample to the standards made up with the manufacturer's buffer. A final validation was carried out by serially diluting a sample to determine whether the detection of VEGF decreased accordingly. The study was commenced after confirming the accuracy of the ELISA under these conditions. Immunoblotting analysis of tissues
The protein samples were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a PVDF membrane at 4°C at 15 V overnight. The membrane was then blocked for a minimum of 2 h in blocking buffer (PBS, 0.1I% Tween 20, 5% Marvel fat-free milk) before incubation with the anti-VEGF rabbit polyclonal antibodies (Zhang et al, 1995) diluted 1:200 in blocking buffer. After washing, the membrane was incubated for 30 min with ['251 ]protein A (Amersham, UK), washed and then exposed directly to radiographic film at -800C.
Statistics
All descriptive and non-parametric statistics were performed using Statview 4.5 (Abacus Concepts, Berkeley, CA, USA). The comparative statistical analysis was calculated using the Mann-Whitney U-test, whereas the correlations were calculated using the Spearman rank correlation. The mean values are presented with the standard error of the mean.
RESULTS VEGF mRNA expression in human breast carcinoma and normal tissues
Fifty-two cases of breast carcinoma were examined for expression of either VEGF mRNA and/or protein (see Table I for clinicopathological details). VEGF mRNA expression was examined in 46 cases, together with matched samples of normal breast tissues resected during mastectomy from 11 of those 46 cases, one case of unmatched normal tissues and four samples of normal tissues from breast reduction specimens (Table 2 ). All tumour and normal samples expressed the isoforms in order of decreasing abundance, 121>165>189, except for one tumour in which the pattern of expression of VEGF was 165>121>189. Although the VEGF 121 isoform was the most abundant species in most cases, there was considerable variation in the extent to which it predominated, ranging from 41 % to 83% of the total VEGF message. In addition, a band of approximately 280 bases was detected in 36 cases of breast carcinoma but not in any of the normal breast tissues. When measuring the levels of VEGF mRNA, initially GAPDH levels were considered as an internal control. However, levels of this enzyme fluctuated sixfold when compared with an external spiked control; when both VEGF mRNA and GAPDH mRNA expression was standardized against an external spiked control, there was a significant correlation between their expression levels (r = 0.77, P < 0.0001, Spearman rank coefficient test). Thus, thereafter, an external spiked control was used to standardize the densitometric signals between samples.
The levels of VEGF mRNA, standardized to an external control, varied up to 70-fold across the tumours (n = 46, mean 18.6 ± 2.6), 20-fold across the normal tissues resected from mastectomy specimens (n = 12, mean 9 ± 3) and two-fold across the normal tissues from mammoplasty tissues (n = 4, mean 8.5 ± 1.7) ( Table 2 ). There was a significant difference between the levels of VEGF mRNA in the tumour compared with all the normal samples (P = 0.02). There was also a significant difference when the reduction mammoplasty samples were excluded, that is only the normal tissues taken from regions adjacent to the tumours were included in the analysis (P = 0.03). When the levels of VEGF mRNA in normal breast and carcinoma tissues taken from the same patient were compared, the VEGF mRNA expression was higher in 9 out of 11 cases (n = 11; normal mean = 9 + 3.3; tumour mean = 15.6 + 5, P = 0.09), but this was not significant, probably reflecting the smaller numbers available for direct comparison (see Figure 1) . The VEGF mRNA expression in EGFR-positive tumours (n = 17; mean 28.6 ± 5.8) was significantly higher than the EGFRnegative cases (n = 29; mean = 13.2 ± 2.3; P < 0.01). There was no significant difference between VEGF mRNA expression in cases negative or positive for ER status (P = 0.09), node status (P = 0.9) or between differing histologies (P = 0.4; n = 39 ductal, five lobular and two other histology subtypes).
The distribution of VEGF mRNA in breast carcinoma The highest levels of VEGF mRNA were detected in the epithelial cells in both normal and malignant tissues (Figure 2) , with the latter expressing higher levels than their normal counterparts. Low levels of VEGF mRNA were detected in the stromal cells of both tumour and normal tissues.
VEGF protein expression in human breast carcinoma and normal tissues The protein levels in the tumours and normal tissue, the latter all from mastectomy specimens, were examined using ELISA (R & D Systems, UK). Having validated the ELISA for use with these samples (see Materials and methods), the subcellular localization of VEGF in samples from the membrane, cytosolic and nuclear fractions of eight tumours and six normal samples taken from mastectomy specimens were examined. In all of the tumour samples examined using ELISA, the highest VEGF concentration (pg per 100 l g total protein) was found in the membrane fraction (see Table 3 ), followed by the cytosolic fraction with lower levels in the nuclear fraction. The membrane VEGF concentration (mean 873 ± 261) was significantly higher than the nuclear fraction (mean 367 ± 165) in the tumour samples (n = 8, P = 0.04) but not the cytosolic fraction (mean 503 ± 156; P = 0.2). In the normal samples, the VEGF concentration highest in the membrane fraction (mean 35.5 ± 5.4), which was significantly higher than the cytosol fraction (cytosol mean 17.2 ± 2.7; n = 6; P = 0.02) but not the nuclear fraction (n = 6, mean 22.7 ± 3.6; P = 0.07). Thus, the membrane fraction was used to measure the levels of VEGF protein in a further 33 tumour and 13 normal samples. In 13 normal samples, the corresponding tumour tissues from the same patient were available for comparison. The VEGF protein expression in the normal samples (n = 15, mean 21.9 i 4.1) differed significantly from that in the tumour samples (n = 38, mean 277 + 68, P < 0.0001) (see Table 2 ).
Furthermore, there was up to sixfold (mean 3.6 ± 0.6) more protein generated per unit mRNA in the 13 matched tumours (mean protein concentration 161 ± 40) compared with the corresponding normal samples (mean protein concentration 15.8 ± 2.8, P < 0.0001) (see Table 4 and Figure 3 ).
There was a strong correlation between the tumour VEGF mRNA and protein levels (n = 38, mRNA mean 18.6 ± 2.6, protein mean 277 ± 68, r = 0.6, P < 0.0007) (Figure 4 ). There was no significant difference in VEGF protein expression in cases positive or negative for EGFR (P = 0.62), ER expression (P = 0.3), node involvement (P = 0.56) or between differing histologies (P = 0.37).
VEGF isoform expression in normal and breast carcinoma samples VEGF165 was the only isoform detected in nine carcinoma and two normal samples using immunoblotting. As with the ELISA, the expression was detected predominantly in the membrane fraction, with some also detected in the cytosolic fraction of samples expressing high levels of VEGF overall. The VEGF protein is detected as a doublet under reducing conditions because of differential glycosylation (Figure 5 ) and was the same size as the recombinant VEGF165 doublet. Although detectable in the membrane fractions of xenografts formed from MCF-7 cells transfected with VEGF121, neither this isoform nor VEGF1 89 was detected in the human breast carcinoma samples.
The expression of elF-4E in normal and breast carcinoma tissues eIF-4E mRNA levels were measured in three normal samples from mastectomy cases, four reduction mammoplasty samples and 44 breast carcinoma cases and standardized against the spiked external control. eIF-4E mRNA expression was detected in two reduction mammoplasty samples, with low levels in the normal tissues from mastectomies. In the three paired normal and tumour samples, the levels of eIF-4E mRNA were between four and British Journal of Cancer (1998) 
75
VEGF mRNA tumour Figure 6 The correlation between elF-4E and VEGF mRNA expression in the 38 tumours examined for both factors (r= 0.58, P = 0.0002). Each was measured by densitometry and standardized against a spiked external control 42-fold higher in the tumours. When the levels of all of the normal tissues (n = 7, normal mean 0.5 ± 0.22, median 0.1) were compared with the tumour tissues examined (n = 42, tumour mean 6.8 ± 0.8, median 4.8), there was a significant difference (P < 0.0001).
In the cases in which both tumour eIF-4E mRNA (mean 6.8 ± 0.8) and VEGF mRNA expression (mean 19.3 ± 2.7) were examined there was a strong correlation (n = 42, r = 0.58, P = 0.0002) (see Figure 6 ), but not between eIF-4E mRNA and VEGF protein expression (r = 0.07, P = 0.98).
DISCUSSION
VEGF mRNA and protein levels correlate with increased microvascular density and a poor prognosis in breast carcinoma (Toi et al, 1994) . High vascular counts in breast tumours as an index of angiogenesis are associated with a significant reduction in survival (Horak et al, 1992; Weidner et al, 1992; Fox et al, 1994) , and thus it is likely that VEGF is partially responsible for breast cancer angiogenesis.
The findings in this study of VEGF mRNA and protein in all samples analysed are in contrast with one report (Toi et al, 1995) and in agreement with another (Yoshiji et al, 1996) . The latter study reported higher VEGF mRNA in 18 breast carcinomas compared with normal breast tissues from the same patients, and detected VEGF immunohistochemically only in the tumour sections. In this study, the mRNA levels in 46 cases and 16 normal samples (11 matched normal tissues, one unmatched and four breast reduction samples) were quantitated using ribonuclease protection assays. The protein levels in 38 cases were measured using ELISA and compared with 13 matched normal samples and two unmatched normal tissues from mastectomies. In addition to there being significant differences between the VEGF expression by tumours and the normal samples at both the mRNA and the protein levels, there was a strong correlation between the mRNA and protein expression. Furthermore, although there was a correlation between mRNA and protein expression, the amount of protein detected in normal tissues was several fold lower than in the tumours for a given level of mRNA. This suggests that VEGF expression is modified post-transcriptionally in tumours compared with normal breast tissue.
There are several possible explanations for this difference. Elevated levels of eIF-4E protein had been reported in breast carcinoma cell lines (Anthony and De Benedetti, 1996) , and in one previous report in which the expression in 38 breast carcinomas was compared with fibroadenomas or breast reduction specimens (Kerekatte et al, 1995) . The same number of tumours was exam- ined in this study, but, in addition, the eIF-4E expression in tumours was compared with normal tissues from the same patient, as well as samples from breast reductions. The eIF-4E mRNA levels were up to 40-fold higher in the tumour samples compared with the paired normal samples. Consistent with the findings of others examining similar samples for eIF-4E protein expression (Kerekatte et al, 1995) , the eIF-4E mRNA levels in reduction mammoplasty samples were very low in two samples and undetectable in two samples. In agreement with the previous report, there was no correlation with ER status (Kerekatte et al, 1995) , nor with EGFR, node status, nor histology.
There was a strong correlation between tumour VEGF mRNA and eIF-4E mRNA levels. As eIF-4E does not regulate VEGF mRNA transcription, this suggests that a common factor regulates both eIF-4E and VEGF mRNA expression resulting in a marked elevation of VEGF protein levels. eIF-4E expression is regulated in response to growth induction by c-myc (Rosenwald et al, 1993) and eIF-4E phosphorylation is regulated by overexpression of ornithine decarboxylase (Shimogori et al, 1996) that is, in turn, regulated when eIF-4E is overexpressed (Shantz et al, 1996) . Recent data have shown that mutant p53 protein regulates VEGF mRNA expression (Kieser et al, 1994) , suggesting a link with tumour progression, and it would be of interest to investigate whether mutant p53 protein also regulates eIF-4E.
There was no correlation between VEGF protein and eIF-4E mRNA levels in the tumours examined. Although eIF-4E protein is reported to correlate with the mRNA levels (Rosenwald et al, 1993; Anthony and De Benedetti, 1996) , the eIF-4E protein has a short half-life compared with the mRNA, is subject to phosphorylation, and therefore the percentage of functional translation initiation factor protein may differ between tumour samples. It is also possible that eIF-4E represents just one mechanism regulating post-transcriptional VEGF expression in malignancy. Other mechanisms include stabilization of the VEGF protein, as when bound to ctI-macroglobulin (Soker et al, 1993) .
The VEGF mRNA levels were significantly higher in EGFR-positive tumours. EGF stimulation of EGFR has been reported to induce VEGF expression in glioblastomas, thereby inducing angiogenesis and resulting in their characteristic vascular appearance (Goldman et al, 1993) , and a similar mechanism may operate in these breast carcinomas. EGFR expression (Nicholson et al, 1988) and increased microvascular density have both been associated with a poor prognosis in breast cancer patients (Fox et al, 1994) . The elevated VEGF is likely to contribute to the increased vessel density, and the association with a poorer prognosis implicates VEGF further as a major angiogenic factor contributing to tumour growth and metastasis.
When measuring the VEGF protein, the highest levels were found in the membrane fraction, with lower levels in the cytosols. VEGF was detected in the nuclear fraction, which may reflect minor contamination of this fraction during preparation and/or translocation of VEGF into the nucleus (Moroianu 1994) . It is less likely to represent artefact as there was a wide variation in expression in the nuclear fractions prepared from different tumours, with no relationship to total cellular VEGF protein levels. Only VEGF165 was detectable using immunoblotting, despite detection of VEGF121, VEGF165 and VEGF189 transcripts. The VEGFI 21 protein may be difficult to detect because it is freely soluble and may bind and be internalized soon after secretion; its detection in the VEGF121 transfectant xenografts, however, confirmed that it can be detected if sufficiently abundant. It is possible, therefore, that antagonists such as suramin could be used to block the angiogenesis induced by the heparinbinding VEGF 165 isoform (Braddock et al, 1994) .
The extent to which the VEGF121 mRNA isoform predominated varied from 41% to 83%, with VEGF165 making up most of the remaining VEGF signal. VEGF189 was detected in all the samples but at a much lower level. In addition to the recognized isoforms, an additional band was detected that may correspond to another splice variant. This was most likely to be the 267-bp fragment described in glioblastomas (Berkman et al, 1993) as it was also detected in the glioblastoma cell line used as a loading control.
In determining the levels of mRNA, several internal and external controls to ensure even loading were assessed. These included the glycolytic enzyme, GAPDH, as an internal control, and the combination of GAPDH sense and antisense probes as an external control. The latter proved to be better as it is not possible to rely upon a gene used as an internal control being expressed equally in all of the samples. In this study, when standardized against an external control, there was a sixfold fluctuation in the levels of the commonly used housekeeping gene, GAPDH, and also a strong significant correlation between GAPDH and VEGF mRNA levels. This may be explained by a factor such as hypoxia, which is present in all solid tumours and which is known to upregulate expression of both genes (Shweiki et al, 1992; Graven et al, 1994) . GAPDH is also up-regulated during proliferation (Meyer et al, 1992; Mansur et al, 1993) , which may explain the elevated levels in some tumours and the lower expression in normal tissues. The co-existence of increased VEGF and GAPDH mRNA expression may indicate a more metabolically active tissue. Given the correlation between VEGF mRNA levels and a poorer prognosis in breast carcinoma (Relf et al, 1997) , an independent comparison of GAPDH and prognosis is warranted.
In summary, significantly elevated levels of VEGF mRNA and protein have been demonstrated in this study in breast carcinomas compared with normal tissues. The cells responsible for this enhanced VEGF expression are the tumour cells, with lower levels of expression by the stromal elements. The VEGF mRNA levels were higher in EGFR-positive cases and correlated with eIF-4E and GAPDH mRNA expression. There was a strong correlation between VEGF mRNA and protein expression. This suggests that VEGF expression in breast carcinoma is controlled by a combination of transcriptional regulation by factors such as hypoxia and EGF, and translational regulation by factors such as eIF-4E. Each factor may itself be subject to regulation: eIF-4E mRNA levels are regulated by hypoxia (unpublished observation), whereas the activity of the protein is modulated by phosphorylation (Rhoads, 1993) .
The greatest difference between tumour and normal breast tissues were amounts of VEGF protein expressed by each. This emphasizes the potential importance of factors such as eIF-4E in tumorigenesis in a common cancer. The role of this transcription initiation factor in malignancy is beginning to emerge, and mechanisms that regulate its expression may be of therapeutic interest.
